US EditionR3 Vascular announces first patient treated in ELITE-BTK pivotal trial - Interventional News
- Cordis announced results from two peripheral studies assessing the SELUTION SLR balloon on April 24, 2025.
- These studies evaluated the device's performance treating complex peripheral artery disease patients.
- Results from one study presented April 23 in London, the other April 25 in Osaka.
- The Japan trial showed 81.5% primary patency at three years in complex patients.
- The data confirms sustained efficacy and safety of the sirolimus balloon for complex PAD treatment.
24 Articles
24 Articles
Rutland Herald
Cordis Announces Positive Results from Two Major Studies Demonstrating Durable Efficacy of SELUTION SLR™ Drug-Eluting Balloon in Complex Peripheral Artery Disease Patients
SELUTION SLR™ Drug-Eluting Balloon (DEB) achieves amongst the highest reported patency for any drug-eluting or drug-coated technology at 3 years in the SELUTION SFA Japan Trial, with 81.5% primary patency.SELUTION SLR™ DEB demonstrates real-world effectiveness and consistency across complex and…
R3 Vascular announces first patient treated in ELITE-BTK pivotal trial - Interventional News
R3 Vascular recently announced that the first patient in its ELITE-BTK pivotal trial has been treated by Brian DeRubertis (New York-Presbyterian and Weill Cornell Medicine, New York, USA). The trial evaluates R3 Vascular’s next-generation drug-eluting bioresorbable scaffold, Magnitude, for below-the-knee (BTK) peripheral arterial disease (PAD). “The treatment of the first patient in our ELITE-BTK pivotal trial by distinguished vascular surgeon a…
Coverage Details
Bias Distribution
- 44% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
